A Retrospective Observational Study of Trifluridine/ Tipiracil (TAS-102) in Chemorefractory Metastatic Colorectal Cancer (mCRC) in Greece. Real World Data on Clinical Benefit.
Latest Information Update: 20 Aug 2022
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms RETRO-TAS
- 02 Jul 2022 Results of an analysis reporting toxicity and efficacy outcomes at median follow-up of 14 months presented at the 24th World Congress on Gastrointestinal Cancer
- 04 Mar 2022 Status changed from recruiting to completed.
- 21 Jul 2021 New trial record